MYX mayne pharma group limited

As far as revenue goes, you may be missing any attribution to...

  1. 335 Posts.
    lightbulb Created with Sketch. 266
    As far as revenue goes, you may be missing any attribution to growth in 2HFY23.
    Sure, 1HFY23 revenue was A$10.44 for about 110,000 cycles so that's an achieved price of $95/cycle.
    For 2HFY23 the CEO has already stated that cycles in December 2022 were 20,000 and by February cycles were growing by 5%/week, so if one was to assume those figures for the remainder of the year, that's about 240,000 cycles for the second half and possibly A$20-25M for 2HFY23.
    So my figures for FY23 are closer to A$35 than $20.

    My projection on this basis, is that we will be exiting June with a weekly sales cycle of between 14,000 to 20,000 and if no further growth occurred in FY2024 we will have sales of between A$70 and A$100 m for FY 24. That's a profitable product, sure not the US$200M projected. With modest 2% weekly growth in FY2024 we are looking at closer to A$140M.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.03
Change
-0.170(3.27%)
Mkt cap ! $408.6M
Open High Low Value Volume
$5.20 $5.21 $5.03 $2.804M 555.6K

Buyers (Bids)

No. Vol. Price($)
2 14654 $5.03
 

Sellers (Offers)

Price($) Vol. No.
$5.14 3111 2
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.